Redox Biology of Respiratory Viral Infections.
Khomich OA, Kochetkov SN, Bartosch B, Ivanov AV. · 2018
Read Redox Biology of Respiratory Viral Infections. by Khomich OA, Kochetkov SN, Bartosch B, Ivanov AV. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6115776.txt.
Introduction
Khomich and co-authors wrote a review in Viruses on redox changes during respiratory virus infections. These viruses cause the common cold and, at times, severe lung illness. Infection shifts the balance of reactive oxygen species in cells. That shift is tied to inflammation and tissue damage.
The review sums up what is known for flu, RSV, rhinovirus, and kin. It covers how each virus stirs up oxidative stress. It also covers how cells try to fight back. Young, old, and weak patients face the highest risk. The authors say this knowledge can guide diagnosis and new treatments.
Catalog record
| CREATOR | Khomich OA, Kochetkov SN, Bartosch B, Ivanov AV. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 109 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Redox Biology of Respiratory Viral Infections By Olga A Khomich, Sergey N Kochetkov, Birke Bartosch, Alexander V Ivanov Published in: Viruses DOI: 10.3390/v10080392 ABSTRACT Abstract Respiratory viruses cause infections of the upper or lower respiratory tract and they are responsible for the common cold—the most prevalent disease in the world. In many cases the common cold results in severe illness due to complications, such as fever or pneumonia. Children, old people, and immunosuppressed patients are at the highest risk and require fast diagnosis and therapeutic intervention. However, the availability and efficiencies of existing therapeutic approaches vary depending on the virus. Investigation of the pathologies that are associated with infection by respiratory viruses will be paramount for diagnosis, treatment modalities, and the development of new therapies. Changes in redox homeostasis in infected cells are one of the key events that is linked to infection with respiratory viruses and linked to inflammation and subsequent tissue damage. Our review summarizes current knowledge on changes to redox homeostasis, as induced by the different respiratory viruses. Keywords: oxidative stress, reactive oxygen species, influenza virus, respiratory syncytial virus, rhinovirus, Nrf2, inflammation 1. INTRODUCTION Redox biology embraces events involving shift of balance between reactive oxygen or nitrogen species (ROS and RNS, respectively) production and their scavenging. Changes of redox status take place during various cellular processes, including proliferation, differentiation, signaling, and metabolism [1]. Redox homeostasis also plays important roles in pathology. Accumulation of ROS or RNS or/and depletion of scavenging systems leads to the development of oxidative stress, chronic activation of immune responses, and inflammation [2]. Due to the ability of ROS to react with almost any kind of biological molecules, including proteins, lipids, and nucleic acids, their chronic elevation is generally associated with genome instability, dysfunction of organelles, and apoptosis [3]. The term “reactive oxygen species” covers short-lived oxygen-containing intermediates with high reactivity. The most extensively studied ROS include superoxide anion (O2•−), hydroxyl radical (HO•), and hydrogen peroxide (H2O2) [4]. The consequences of their production and corresponding antioxidant pathway, activated in response to it, depend on the location in a cell. An example of a well characterized source of O2•− is the electron transfer to oxygen that occurs during respiration in mitochondria. A predominant ROS-scavenging enzyme that is implicated in neutralization of O2•− in mitochondria is superoxide dismutase 2 (SOD2 or MnSOD) [5]. SOD2 converts O2•− to H2O2, which in turn, can be metabolized by different enzymes, including catalase (CAT), peroxiredoxins (Prdx), or glutathione peroxidases (GPx) [6]. An extensive description of the various cellular ROS sources and scavenging enzymes and pathways are described further below and in the following comprehensive reviews [7,8]. Markers of redox misbalance in blood and tissues are often taken into account in the pathology of various diseases. Chronic viral hepatitis B and C are generally associated with oxidative stress, and levels of ROS and oxidized metabolites correlate with the severity of liver damage and with the risk of the development of related pathologies—fibrosis and hepatocellular carcinoma [9]. Moreover, currently redox biology pays much attention to localization of ROS sources, since local changes in ROS levels may influence signaling pathways by activating “redox switches” [10,11]. In lungs, redox homeostasis is crucial in the pathology of asthma [12]. Lung infection with respiratory viruses is, in general, associated with cytokine production, inflammation, cell death, and other pathological processes, which could be triggered by enhanced ROS production. Investigation of the influence of these infections on ROS-producing and ROS-scavenging enzymes and systems may allow for the identification of those that are crucial for replication of the pathogens and occurrence of virus-associated disease. Our review aims to summarize the known data on the role of redox biology in the pathologies that are associated with infection with respiratory viruses. 2. RESPIRATORY VIRUSES Respiratory infections comprise a group of diseases that affect millions of people worldwide and pose threat to many of them, especially for kids and elderly. Respiratory viruses cause infections of the upper or lower respiratory tract. The group of respiratory viruses comprises influenza (IV), human respiratory syncytial (HRSV), human rhino (HRV), human metapneumo (HMPV), parainfluenza, and adeno- and corona-viruses (severe acute respiratory syndrome coronavirus SARS-CoV). Many of them cause common clinical syndromes, including nasal congestion, cough, sore throat, and fever, although some of these pathogens may also display more specific clinical manifestations, such as bronchiolitis, pneumonia, etc. (discussed below in this section). 2.1. Influenza Viruses Influenza viruses are RNA viruses belonging to the Orthomyxoviridae family [13]. Three IVs are infectious for humans, namely types A, B, and C. The IV genome consists of eight segments (seven for influenza C virus) encoding 9–11 proteins, depending on the type of virus. These proteins include the surface proteins hemagglutinin (HA) and neuraminidase (NA), three subunits of RNA polymerase (PA, PB1, and PB2), two non-structural proteins (NS1 and NEP), and two matrix proteins (M1 and a selective proton channel protein M2). Various subtypes of the most common influenza A viruses are classified based on the diversity in the structure of HA and NA proteins. Influenza A and B viruses cause epidemics, whereas influenza C virus is less wide spread and tends to cause infections with less severe symptoms. According to the World Health Organization (WHO), seasonal epidemics that are associated with these infections result in 3 to 5 million cases of severe illness each year, and 250 to 500 thousands deaths worldwide [14]. Currently, safe and effective vaccines are available. However, their specificity is limited to a particular subtype of the virus due to the diversity of circulating influenza A strains and ability of IV to rapidly accumulate mutations (viral antigenic drift). So, often these vaccines do not perfectly match the circulating subtype or become ineffective within short amounts of time due to viral antigenic drift, thus requiring the annual re-fabrication of vaccines and revaccination. Treatment options for IV infections are limited to inhibitors of neuraminidase, which prevent virion release and spread, but not replication [15] and blockers of the M2 proton channel [16]. However, the development of drug resistance is an important issue. Due to the high prevalence of IV serotypes that are resistant to adamantane antiviral drugs, the WHO recommends neuraminidase inhibitors instead of M2 proton channel blockers (amantadine and rimantadine) [14]. 2.2. Human Respiratory Syncytial Virus Human respiratory syncytial virus belongs to the Pneumoviridae family of RNA viruses [17]. The viral genome is represented by a single-stranded negative-sense 15.2 kb RNA encoding 11 proteins. Similarly to IV, HRSVs are classified as A or B genotypes, according to the structure of fusion (F) and attachment (G) proteins. The rest of the viral proteome includes proteins N, M, P, SH, L (polymerase), M2-1, M2-2, and NS1, NS2. HRSV is a leading cause of bronchiolitis and pneumonia in children, especially in pre-mature infants and children with cardiac or pulmonary diseases. It was also shown that HRSV significance in adults is comparable to nonpandemic IV [18]. The group of risk includes the elderly and immunocompromised people. Approximately 33 million cases of infection are reported annually worldwide [19,20]. No HRSV vaccine is available yet. The only prophylactic treatment option, palivizumab (Synagis®)—a monoclonal antibody against the F viral protein is recommended for HRSV prevention and the treatment of infants at high risk of severe